The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
Open accessAbstract
Abstract At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the high treatment burden in this patient population. PulmoSphere™ technology is an emulsion-based spray-drying process that enables the production of light porous particle, dry-powder formulations, which exhibit improved flow and dispersion from passive dry powder inhalers. This review explores the fundamental characteristics of PulmoSphere technology, focusing on the development of a dry powder formulation of tobramycin for the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in CF patients. This dry powder formulation provides substantially improved intrapulmonary deposition efficiency, faster delivery, and more convenient administration over nebulized formulations. The availability of more efficient and convenient treatment options may improve treatment compliance, and thereby therapeutic outcomes in CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Martindale: the complete drug reference
(2005) · Choice Reviews Online · doi:10.5860/choice.42-6228 · Cited by 2,688
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Konstan, M. W., Flume, P. A., Kappler, M., Chiron, R., Higgins, M., Brockhaus, F., Zhang, J., Angyalosi, G., He, E., & Geller, D. E. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.10.003 · Cited by 314
Self-citationPharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis
Geller, D. E., Pitlick, W. H., Nardella, P. A., Tracewell, W. G., & Ramsey, B. W. (2002) · Chest · doi:10.1378/chest.122.1.219 · Cited by 300
Self-citationEfficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., & Cooper, P. J. (2009) · Chest · doi:10.1378/chest.08-1421 · Cited by 281
Lung Biology in Health and Disease
(2010) · Lung biology in health and disease · doi:10.1201/ihclubihedis · Cited by 256
Submicron Emulsions in Drug Targeting and Delivery
(2019) · CRC Press eBooks · doi:10.1201/9780367810528 · Cited by 199
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
Geller, D. E., Konstan, M. W., Smith, J., Noonberg, S. B., & Conrad, C. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20594 · Cited by 196
Self-citationHollow Porous Particles in Metered Dose Inhalers
Dellamary, L. A., Tarara, T. E., Smith, D. J., Woelk, C. H., Adractas, A., Costello, M. L., Gill, H., & Weers, J. G. (2000) · Pharmaceutical Research · doi:10.1023/a:1007513213292 · Cited by 179
Self-citationTobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial
Konstan, M. W., Geller, D. E., Minić, P., Brockhaus, F., Zhang, J., & Angyalosi, G. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21356 · Cited by 166
Self-citationAerosol Antibiotics in Cystic Fibrosis
Geller, D. E. (2009) · Respiratory Care · doi:10.4187/aarc0537 · Cited by 160
Self-citationImproved Lung Delivery from a Passive Dry Powder Inhaler Using an Engineered PulmoSphere® Powder
Duddu, S. P., Sisk, S. A., Walter, Y. H., Tarara, T. E., Trimble, K. R., Clark, A. R., Eldon, M. A., Elton, R. C., Pickford, M., Hirst, P. H., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1015322616613 · Cited by 150
Self-citationANDERSON, P. J. (1997) · CHEST Journal · doi:10.1378/chest.111.5.1155 · Cited by 150
Design of fine particles for pulmonary drug delivery
Weers, J. G., Tarara, T. E., & Clark, A. R. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.3.297 · Cited by 125
Self-citationParticulate Interactions in Dry Powder Formulation for Inhalation
Zeng, X. M., Martin, G. P., & Marriott, C. (2000) · CRC Press eBooks · doi:10.3109/9780203209592 · Cited by 125
Pulmonary Formulations: What Remains to be Done?
Weers, J. G., Bell, J., Chan, H., Cipolla, D. C., Dunbar, C., Hickey, A. J., & Smith, I. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2010.0838 · Cited by 109
Self-citationAdherence with tobramycin inhaled solution and health care utilization
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-5 · Cited by 95
Infection control in cystic fibrosis: barriers to implementation and ideas for improvement
Saiman, L. M., & Garber, E. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328330d974 · Cited by 13
Adherence to Tobramycin Inhaled Solution and Health Care Utilization.
Briesacher, B., Quittner, A. L., Saiman, L. M., Fouayzi, H., Sacco, P., & Quittel, L. (2009) · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1183 · Cited by 6
Cited by
The use of natural and synthetic phospholipids as pharmaceutical excipients
van Hoogevest, P., & Wendel, A. (2014) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201400219 · Cited by 418
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 393
Drug Delivery to the lungs: Challenges and Opportunities
Newman, S. P. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0037 · Cited by 328
Technological and practical challenges of dry powder inhalers and formulations
Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.04.004 · Cited by 303
Dry powder inhalation: past, present and future
de Boer, A. H., Hagedoorn, P., Hoppentocht, M., Buttini, F., Grasmeijer, F., & Frijlink, H. W. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1224846 · Cited by 271
Metadata
- Authors
- Geller, D. E., Weers, J., & Heuerding, S.
- Venue
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Publisher
- SAGE Publications
- Published
- 2011-08
- Volume
- 24
- Issue
- 4
- Pages
- 175-182
- ISSN
- 1941-2703 (ISSN-L)
- 1941-2711
- OpenAlex
- W2058889783
- Cited by
- 308
- References
- 23
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.